

Corresponding author(s):	Nozomu Obana
Last updated by author(s):	Jul 7, 2020

# **Reporting Summary**

**x** Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

Sta	itis	tics			
For	all st	tatistical analys	ses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed				
x		The exact san	nple size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement		
x		A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
x	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
x		A description	of all covariates tested		
X		A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
x			tion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) in (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
x		For Bayesian	analysis, information on the choice of priors and Markov chain Monte Carlo settings		
x		For hierarchic	cal and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
x		Estimates of e	effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated		
			Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
So	ftw	vare and o	code		
Poli	cy in	formation abo	out <u>availability of computer code</u>		
Data collection		ollection	Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR state that no software was used.		
Data analysis		inalysis	Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.		
			tom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.		
Da	ta				
All	mar - Acc - A lis	nuscripts must ession codes, ur st of figures that	out <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: nique identifiers, or web links for publicly available datasets have associated raw data y restrictions on data availability		
Provide your data availability statement here.					
Fi	elo	d-speci	ific reporting		

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size The presented figure are a representative dataset derived from experiments having at least 3 biological replicates. Sample sizes were chosen arbitrarily as the minimum required to establish reproducibility.

Data exclusions No data were excluded from the study. For blots and images, representative data are shown.

Replication The data presented in this study are derived from experiments having at least 3 biological replicates.

Randomization This was not required in our study.

Blinding This was not required in our study.

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

stadies mast alsolose on these points even when the alsolosare is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample

State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale

for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether

Timing Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Data exclusions | If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization | If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

# Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets,

any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Timing and spatial scale Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which

(1	the data are taken				
	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.				
,	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.				
	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.				
S	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.				
Did the study involve field	work? Yes No				
ield work, collecti	on and transport				
Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).				
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).				
Access and import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).				
Disturbance	Describe any disturbance caused by the study and how it was minimized.				
Materials & experimental systems    Materials & experimental systems   Methods					
	This study used anti-RsaA anti-DilA2 and anti-ELAG primary anti-body (Make 014 22292). Anti-RsaA and anti-DilA2 word				
Antibodies used	This study used anti-BsaA, anti-PilA2, and anti-FLAG primary antibody (Wako, 014-22383). Anti-BsaA and anti-PilA2 were generated by immunization of purified His-tagged BsaA or PilA2 proteins to rabbits. The immunization and collection of the sera were supported by eurofin Genomics.				
Validation	Primary antibody specificity was checked by western blotting whether the expected protein bands were undetectable from the deletion mutant (bsaA or pilA2) or wild-type strain (FLAG).				
Eukaryotic cell line	es S				
olicy information about <u>cell</u>	lines				
Cell line source(s)	State the source of each cell line used.				
Authentication	Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.				
Mycoplasma contaminatio	Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.				
Commonly misidentified lin (See ICLAC register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.				

## Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

## Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

Wild animals

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about studies involving human research participants

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol

Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

#### ChIP-sea

#### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such
--

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

#### Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session (e.g. UCSC)

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

### Methodology

Replicates Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone

Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and

index files used.

Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

ennemmen

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

### Flow Cytometry

#### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- **x** A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation
Biofilms were disrupted by thoroughly pipetting, and the cells were collected by centrifugation. The cells were suspended in 4% formaldehyde/PBS for 10 min. After fixation, the cells were washed with PBS, resuspended in PBS and stored at 4°C.

Instrument SH800 flow cytometer (Sony)

Software Flowjo 10.7

Cell population abundance Not applicable in this study

Gating strategy Not applicable in this study

x Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

#### Experimental design

Design type Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition		
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.	
Field strength	Specify in Tesla	
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size slice thickness, orientation and TE/TR/flip angle.	
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determine	
Diffusion MRI Used	Not used	
Preprocessing		
Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).	
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.	
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.	
Noise and artifact removal	Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).	
Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.	
Statistical modeling & inference		
Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).	
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.	
Specify type of analysis: Who	prain ROI-based Both	
Statistic type for inference (See <u>Eklund et al. 2016</u> )	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.	
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).	
Models & analysis  n/a   Involved in the study		
Functional and/or effective connec	Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).	
Graph analysis	Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).	
Multivariate modeling and predictive	Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.	